Antiplatelet therapy in type 2 MI

P.J. Devereaux

Dr P.J. Devereaux is a professor in the Department of Health Research Methods, Evidence, and Impact and Department of Medicine and director of the Division of Cardiology at McMaster University.

What is the recommended antiplatelet therapy in a patient with type 2 myocardial infarction (MI)?

P.J. Devereaux, MD, PhD: With type 2 MI you have to ask the question, “Is this likely due to underlying significant atherosclerotic disease?” If it is, then certainly use dual antiplatelet therapy. Probably aspirin and ticagrelor would be used most commonly choice in today’s world with those patients.

We would love to hear from you

  • Do you have any comments?
  • Have you found a mistake?
  • Would you like to suggest a feature?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.